Cost‐effectiveness of generic pan‐genotypic sofosbuvir/velpatasvir versus genotype‐dependent direct‐acting antivirals for hepatitis C treatment-Reference-Cited by-同舟云学术

Cost‐effectiveness of generic pan‐genotypic sofosbuvir/velpatasvir versus genotype‐dependent direct‐acting antivirals for hepatitis C treatment

Author:

Goel Amit¹^ORCID,Chen Qiushi²³⁴,Chhatwal Jagpreet³⁴,Aggarwal Rakesh¹^ORCID

Affiliation:

1. Department of GastroenterologySanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India

2. Harold and Inge Marcus Department of Industrial and Manufacturing EngineeringPenn State University State College Pennsylvania USA

3. Massachusetts General Hospital Institute for Technology Assessment Boston Massachusetts USA

4. Harvard Medical School Boston Massachusetts USA

Funder

World Health Organization

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

Reference34 articles.

5. AASLD/IDA.HCV guidance: recommendations for testing managing and treating hepatitis C.https://www.hcvguidelines.org/. Accesssed 17 December 2017.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost effectiveness of hepatitis C direct acting agents;Expert Review of Pharmacoeconomics & Outcomes Research;2024-05-03